Aurore Rauscher
Nantes, 44000, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Prospective pilot study with [89Zr]Zr-girentuximab PET/CT: CA-IX imaging in metastatic triple negative breast cancer (OPALESCENCE).
Journal: European journal of nuclear medicine and molecular imaging
Published: July 10, 2025
Comparison of Hormone-Sensitive Oligorecurrent Prostate Cancer Patients Based on Routine Use of Choline and/or PSMA PET/CT to Guide Metastasis-Directed Therapy.
Journal: Cancers
Published: February 02, 2023
Prospective Multicentric Assessment of 68Ga-DOTANOC PET/CT in Grade 1-2 GEP-NET.
Journal: Cancers
Published: December 04, 2022
Quantitative impact of the first COVID-19 lockdown on nuclear medicine in France: the CORALINE study.
Journal: European journal of nuclear medicine and molecular imaging
Published: February 09, 2021
Head-to-Head Comparison of 18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT in Patients With Midgut Neuroendocrine Tumors.
Journal: Clinical nuclear medicine
Published: December 14, 2020
Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC Study.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: July 08, 2020
Promising clinical performance of pretargeted immuno-PET with anti-CEA bispecific antibody and gallium-68-labelled IMP-288 peptide for imaging colorectal cancer metastases: a pilot study.
Journal: European journal of nuclear medicine and molecular imaging
Published: April 24, 2020
Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: September 06, 2019
Preliminary results of a 68 Ga-PSMA PET/CT prospective study in prostate cancer patients with occult recurrence: Diagnostic performance and impact on therapeutic decision-making.
Journal: The Prostate
Published: March 28, 2019
Clinical Results in Medullary Thyroid Carcinoma Suggest High Potential of Pretargeted Immuno-PET for Tumor Imaging and Theranostic Approaches.
Journal: Frontiers in medicine
Published: February 19, 2019
68Ga-PSMA-11 PET-CT study in prostate cancer patients with biochemical recurrence and non-contributive 18F-Choline PET-CT: Impact on therapeutic decision-making and biomarker changes.
Journal: The Prostate
Published: October 05, 2018
Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and 68Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: January 06, 2016
Last Updated: 09/26/2026